comparemela.com
  1. Home
  2. Live Updates
  3. Lee Symptom Scale - Breaking News

Latest Breaking News On - Lee symptom scale - Page 1 : comparemela.com

PROs for Cutaneous Chronic GVHD After Transplant Tied to Disease Severity, Mortality

Baseline QOL, symptom burden could inform risk stratification, treatment decisions

University of pennsylvaniaUnited statesSandra mitchellEdward cowenCharles bankheadEmily baumrinNational cancer institute in rockvillePopulation sciencesDivision of cancerCancer controlNational cancer instituteDermatology branchNational instituteSkin diseasesFunctional assessmentCancer therapy bone marrow transplantation

Axatilimab Gets Priority Review for Chronic Graft-vs-Host Disease

The application is supported by data from the phase 2 AGAVE-201 study.

Drug administrationPriority reviewBiologics license applicationLee symptom scalePrescription drug user fee act

Form 424B5 Syndax Pharmaceuticals

Form 424B5 Syndax Pharmaceuticals
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNew yorkSan diegoHong kongState of new yorkState of delawareDistrict of columbiaState of israelLukej albrechtKaplan meierLuke albrechtCompany overviewGoldman sachsAmerican society of hematologyCompanies winding

Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD

Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.

United statesDaniel wolffNational institutes of healthUniversity hospital of regensburgUniversity hospitalPlenary sessionNational institutesNorth americaMiddle eastLee symptom scale

Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

WILMINGTON, Del. & WALTHAM, Mass. (BUSINESS WIRE) Dec 10, 2023

United statesSan diegoKaplan meierMichaela metzgerSharon klahreDaniel wolffPabloj cagnoniExchange commissionDrug administrationHead of researchCompany on twitterProfessor at university hospital regensburgSyndax pharmaceuticals nasdaqSyndax pharmaceuticalsAmerican society of hematology annual meetingDevelopment incyte

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.